Bevacizumab (Avastin®), which blocks angiogenesis by binding to VEGF and inhibiting its interaction with VEGFR1/2 receptors, is approved for the treatment of several cancer types, including metastatic colorectal cancer (CRC), NSCLC, and RCC [96]. This evidence concerns the gene FLT1 and renal cell carcinoma.